| Title |
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, April 2012
|
| DOI | 10.1007/s00262-012-1254-0 |
| Pubmed ID | |
| Authors |
Grazyna Lipowska-Bhalla, David E. Gilham, Robert E. Hawkins, Dominic G. Rothwell |
| Abstract |
The adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a relatively new but promising approach in the field of cancer immunotherapy. This therapeutic strategy is based on the genetic reprogramming of T cells with an artificial immune receptor that redirects them against targets on malignant cells and enables their destruction by exerting T cell effector functions. There has been an explosion of interest in the use of CAR T cells as an immunotherapy for cancer. In the pre-clinical setting, there has been a considerable focus upon optimizing the structural and signaling potency of the CAR while advances in bio-processing technology now mean that the clinical testing of these gene-modified T cells has become a reality. This review will summarize the concept of CAR-based immunotherapy and recent clinical trial activity and will further discuss some of the likely future challenges facing CAR-modified T cell therapies. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 215 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 2% |
| Germany | 3 | 1% |
| United States | 3 | 1% |
| Canada | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 203 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 36 | 17% |
| Researcher | 35 | 16% |
| Student > Ph. D. Student | 34 | 16% |
| Student > Master | 29 | 13% |
| Student > Doctoral Student | 14 | 7% |
| Other | 33 | 15% |
| Unknown | 34 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 65 | 30% |
| Biochemistry, Genetics and Molecular Biology | 35 | 16% |
| Medicine and Dentistry | 34 | 16% |
| Immunology and Microbiology | 20 | 9% |
| Chemistry | 7 | 3% |
| Other | 15 | 7% |
| Unknown | 39 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2024.
All research outputs
#2,022,938
of 23,477,147 outputs
Outputs from Cancer Immunology, Immunotherapy
#70
of 2,932 outputs
Outputs of similar age
#12,600
of 164,184 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#2
of 31 outputs
Altmetric has tracked 23,477,147 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,932 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,184 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.